רווח למניה בשנים עשר החודשים האחרונים: OncoCyte Corp (OCX)

OncoCyte Corporation (OCX) is optimizing AI tumor analysis via cloud services to eliminate infrastructure risks. Stable demand for early cancer diagnostics ensures predictable cash flow and high margins. Revenue is generated through the sale of genomic tests for pathologists. The company's TTM net income per share on the GURU.Markets chart reflects a trend with the metric valued at -3.53.

OncoCyte Corporation is developing high-tech methods for the early detection of oncology. GURU.Markets tools allow for tracking changes in per-share profit over the last 12 months to assess the effectiveness of this strategy. This indicator divides total net income by the total number of shares, isolating the impact of issuance. In the biopharmaceutical sector, sharp spikes in this metric often signal temporary anomalies. Stable growth of the indicator confirms the commercial viability of the diagnostic systems.